Affordable Access

Publisher Website

Cardiotoxicity of systemic agents used in breast cancer

Authors
Journal
The Breast
0960-9776
Publisher
Elsevier
Identifiers
DOI: 10.1016/j.breast.2014.04.002
Keywords
  • Breast Cancer
  • Cardiotoxicity
  • Chemotherapy
  • Anti-Her2 Agents
  • Endocrine Therapy
  • Biomarkers
Disciplines
  • Biology
  • Medicine

Abstract

Abstract Several breast cancer therapies can lead to cardiovascular toxicity: drugs such anthracyclines can cause permanent damage, anti-HER2 agents may cause transitory and reversible cardiac dysfunction and others, such as those used in endocrine therapy, primarily disturb lipid metabolism. Considering the seriousness of these complications, trials are now being conducted to address cardiotoxicity associated with new drugs; however, to fully understand their toxicity profiles, longer follow-up is needed. In this review, we compile the information available about cardiac toxicity related to well-established systemic breast cancer treatments, as well as newer drugs, including antiangiogenics, mTOR inhibitors and novel anti-HER2 agents. We also describe current and next generation cardiac biomarkers and functional tests that can optimize treatment and reduce and prevent the incidence of treatment-related cardiotoxicity

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

[Significant cardiotoxicity of trastuzumab in adju...

on Strahlentherapie und Onkologie... July 2014

Adjuvant early breast cancer systemic therapies ac...

on Critical Reviews in Oncology/H...

Adjuvant early breast cancer systemic therapies ac...

on Critical Reviews in Oncology/H... Jan 01, 2012
More articles like this..